<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/212165#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:Evidence rdf:ID="Evidence39">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep89">
 <bp:stepProcess rdf:resource="#BiochemicalReaction80" />
 <bp:stepProcess rdf:resource="#Catalysis8" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence35">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence139">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence36">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence138">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence37">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence38">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence135">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence134">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence137">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence136">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence131">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence130">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence133">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence132">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence140">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep90">
 <bp:stepProcess rdf:resource="#BiochemicalReaction81" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep91">
 <bp:stepProcess rdf:resource="#BiochemicalReaction82" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep94">
 <bp:stepProcess rdf:resource="#Catalysis9" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction85" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep95">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence33">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep92">
 <bp:stepProcess rdf:resource="#BiochemicalReaction83" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence34">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep93">
 <bp:stepProcess rdf:resource="#BiochemicalReaction84" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep98">
 <bp:stepProcess rdf:resource="#Catalysis12" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep99">
 <bp:stepProcess rdf:resource="#BiochemicalReaction89" />
 <bp:stepProcess rdf:resource="#Catalysis13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep96">
 <bp:stepProcess rdf:resource="#Catalysis10" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction86" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep97">
 <bp:stepProcess rdf:resource="#Catalysis11" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction87" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence142">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence141">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep69">
 <bp:stepProcess rdf:resource="#BiochemicalReaction61" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep67">
 <bp:stepProcess rdf:resource="#BiochemicalReaction59" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep68">
 <bp:stepProcess rdf:resource="#BiochemicalReaction60" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction1" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction16" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction45" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction4" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction9" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep72">
 <bp:stepProcess rdf:resource="#BiochemicalReaction64" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis8">
 <bp:controlled rdf:resource="#BiochemicalReaction80" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep73">
 <bp:stepProcess rdf:resource="#BiochemicalReaction65" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis9">
 <bp:controlled rdf:resource="#BiochemicalReaction85" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction57" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep70">
 <bp:stepProcess rdf:resource="#BiochemicalReaction62" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep71">
 <bp:stepProcess rdf:resource="#BiochemicalReaction63" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction79" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep76">
 <bp:stepProcess rdf:resource="#BiochemicalReaction68" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep77">
 <bp:stepProcess rdf:resource="#BiochemicalReaction69" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep74">
 <bp:stepProcess rdf:resource="#BiochemicalReaction66" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep75">
 <bp:stepProcess rdf:resource="#BiochemicalReaction67" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep78">
 <bp:stepProcess rdf:resource="#BiochemicalReaction70" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep79">
 <bp:stepProcess rdf:resource="#BiochemicalReaction71" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#Catalysis2" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#Catalysis1" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep80">
 <bp:stepProcess rdf:resource="#BiochemicalReaction72" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep83">
 <bp:stepProcess rdf:resource="#BiochemicalReaction75" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep84">
 <bp:stepProcess rdf:resource="#BiochemicalReaction76" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep81">
 <bp:stepProcess rdf:resource="#BiochemicalReaction73" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep82">
 <bp:stepProcess rdf:resource="#BiochemicalReaction74" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep87">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep88">
 <bp:stepProcess rdf:resource="#BiochemicalReaction79" />
 <bp:stepProcess rdf:resource="#Catalysis7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep85">
 <bp:stepProcess rdf:resource="#BiochemicalReaction77" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep86">
 <bp:stepProcess rdf:resource="#BiochemicalReaction78" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep47">
 <bp:stepProcess rdf:resource="#BiochemicalReaction39" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep48">
 <bp:stepProcess rdf:resource="#BiochemicalReaction40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep45">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep46">
 <bp:stepProcess rdf:resource="#BiochemicalReaction38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep49">
 <bp:stepProcess rdf:resource="#BiochemicalReaction41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep50">
 <bp:stepProcess rdf:resource="#BiochemicalReaction42" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep51">
 <bp:stepProcess rdf:resource="#BiochemicalReaction43" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep54">
 <bp:stepProcess rdf:resource="#BiochemicalReaction46" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep55">
 <bp:stepProcess rdf:resource="#BiochemicalReaction47" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep52">
 <bp:stepProcess rdf:resource="#BiochemicalReaction44" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep53">
 <bp:stepProcess rdf:resource="#Catalysis5" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction45" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep58">
 <bp:stepProcess rdf:resource="#BiochemicalReaction50" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep59">
 <bp:stepProcess rdf:resource="#BiochemicalReaction51" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence109">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep56">
 <bp:stepProcess rdf:resource="#BiochemicalReaction48" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep57">
 <bp:stepProcess rdf:resource="#BiochemicalReaction49" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence106">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence105">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence108">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence107">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence102">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence101">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence104">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence103">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence100">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep61">
 <bp:stepProcess rdf:resource="#BiochemicalReaction53" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep62">
 <bp:stepProcess rdf:resource="#BiochemicalReaction54" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep60">
 <bp:stepProcess rdf:resource="#BiochemicalReaction52" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep65">
 <bp:stepProcess rdf:resource="#Catalysis6" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction57" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep66">
 <bp:stepProcess rdf:resource="#BiochemicalReaction58" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep63">
 <bp:stepProcess rdf:resource="#BiochemicalReaction55" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep64">
 <bp:stepProcess rdf:resource="#BiochemicalReaction56" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#BiochemicalReaction21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#BiochemicalReaction24" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence117">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence116">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction22" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence119">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#BiochemicalReaction23" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence118">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence113">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence112">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence115">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence114">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence111">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence110">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep32">
 <bp:stepProcess rdf:resource="#BiochemicalReaction27" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep33">
 <bp:stepProcess rdf:resource="#BiochemicalReaction28" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#BiochemicalReaction25" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#BiochemicalReaction26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep36">
 <bp:stepProcess rdf:resource="#BiochemicalReaction31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep37">
 <bp:stepProcess rdf:resource="#BiochemicalReaction32" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep34">
 <bp:stepProcess rdf:resource="#BiochemicalReaction29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep35">
 <bp:stepProcess rdf:resource="#BiochemicalReaction30" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence128">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence127">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep38">
 <bp:stepProcess rdf:resource="#BiochemicalReaction33" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep39">
 <bp:stepProcess rdf:resource="#BiochemicalReaction34" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence129">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence124">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence123">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence126">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence125">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence120">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence122">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence121">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep40">
 <bp:stepProcess rdf:resource="#BiochemicalReaction35" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep43">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep44">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep41">
 <bp:stepProcess rdf:resource="#BiochemicalReaction36" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep42">
 <bp:stepProcess rdf:resource="#BiochemicalReaction37" />
</bp:PathwayStep>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:Evidence rdf:ID="Evidence90">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence91">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence92">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence97">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence98">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence99">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence93">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence94">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence95">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence96">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence80">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence81">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence86">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence87">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence88">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence89">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence82">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence83">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence84">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence85">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence79">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence70">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence75">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence76">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence77">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence78">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence71">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence72">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence73">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence74">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence68">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence69">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence64">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence65">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence66">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence67">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence60">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence61">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence62">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence63">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence57">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence58">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence59">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence53">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence54">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence55">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence56">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence50">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence51">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence52">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence46">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence47">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence48">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence49">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence42">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence43">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence44">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence45">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence40">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence41">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Positive epigenetic regulation of rRNA expression</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcription of rRNA genes is controlled by epigenetic activation and repression according to the metabolic requirements of the cell (reviewed in Percipalle and Farrants 2006, McStay and Grummt 2008, Goodfellow and Zomerdijk 2012, Grummt and Langst 2013). Depending on the growth state of the cell, about half of the approximately 400 rRNA genes are expressed and these have the modifications characteristic of active chromatin: unmethylated DNA and acetylated histones. Repressed genes generally have methylated DNA and histone H3 methylated at lysine-9. Regulators of activation include ERCC6 (CSB), histone acetylases such as KAT2B (PCAF), and the B-WICH complex. Dysregulation of RNA polymerase I transcription plays a role in disease (reviewed in Hannan et al. 2013). The B-WICH complex positively regulates rRNA expression by remodeling chromatin and recruiting histone acetyltransferases that modify histones to transcriptionally active states ERCC6 (CSB) and EHMT2(G9a) positively regulate rRNA expression by ERCC6 recruiting the histone methyltransferase EHMT2 (also known as G9a) which dimethylates histone H3 at lysine-9 within the transcribed regions of rRNA genes. ERCC6 (CSB) and KAT2B (PCAF) positively regulate rRNA expression by ERCC6 recruiting the histone acetyltransferase KAT2B to the promoter where KAT2B acetylates histone H4 at several lysine residues and histone H3 at lysine-9. The acetylated chromatin facilitates the assembly of RNA polymerase I initiation complex.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep122" />
 <bp:pathwayOrder rdf:resource="#PathwayStep101" />
 <bp:pathwayOrder rdf:resource="#PathwayStep137" />
 <bp:pathwayOrder rdf:resource="#PathwayStep95" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep87" />
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:pathwayComponent rdf:resource="#Pathway19" />
 <bp:pathwayComponent rdf:resource="#Pathway16" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Epigenetic regulation of gene expression</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Epigenetic processes regulate gene expression by modulating the frequency, rate, or extent of gene expression in a mitotically or meiotically heritable way that does not entail a change in the DNA sequence. Originally the definition applied only to heritability across generations but later also encompassed the heritable changes that occur during cellular differentiation within one organism.  Molecular analysis shows epigenetic changes comprise covalent modifications, such as methylation and acetylation, to DNA and histones. RNA interference has been implicated in the initiation of some epigenetic changes, for example transcriptional silencing of transposons. Proteins which bind to the modified DNA and histones are then responsible for repressing transcription and for maintaining the epigenetic modifications during cell division. During differentiation, patterns of gene expression are established by polycomb complexes PRC1 and PRC2. PRC2 methylates histones and DNA to produce the initial marks of repression: trimethylated lysine-27 on histone H3 (H3K27me3) and 5-methylcytosine in DNA. PRC2, through its component EZH2 or, in some complexes, EZH1 trimethylates lysine-27 of histone H3. The H3K27me3 produced by PRC2 is bound by the Polycomb subunit of PRC1. PRC1 ubiquitinates histone H2A and maintains repression. PRC2 and other epigenetic systems modulate gene expression through DNA methyation, the transfer of a methyl group from S-adenosylmethionine to the 5 position of cytosine in DNA by a family of DNA methyltransferases (DNMTs): DNMT1, DNMT3A, and DNMT3B. In the reverse process TET1,2,3 and TDG demethylate DNA through the oxidation of the methyl group of 5-methylcytosine by TET enzymes and the excision of the oxidized product (5-formylcytosine or 5-carboxylcytosine) by TDG. Ribosomal RNA (rRNA) genes are activated and deactivated according to the metabolic requirements of the cell. Positive epigenetic regulation of rRNA expression occurs through chromatin modifications produced by activators such as ERCC6 (CSB), the B-WICH complex, and histone acetylases such as KAT2B (PCAF). Negative epigenetic regulation of rRNA expression occurs through chromatin modifications produced by repressors such as the eNoSC complex, SIRT1, and the NoRC complex.  WDR5 is a component of six histone methyltransferases and three histone acetyltransferases involved in epigenetic regulation of gene expression (reviewed in Guarnaccia and Tansey 2018).  Endogenous retroelements are transposable elements that transpose to new genomic locations via an RNA intermediate and reverse transcription. Retroelements are silenced epigenetically in the human genome by mechanisms that include PIWI-interacting small RNAs (piRNAs) that transcriptionally silence retroelements through an RNA interference mechanism, KRAB-ZFP zinc finger-type repressors that bind specific DNA sequences in retroelements, and the HUSH complex that recognizes retroelements through nascent RNA or through existing histone H3 lysine-9 trimethylation (Almeida et al. 2022).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">B-WICH recruits histone acetyltransferases</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction92">
 <bp:evidence rdf:resource="#Evidence105" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NuRD complex binds SUMO2-6K-TRIM28:KRAB-ZNF:retroelement</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">B-WICH complex binds rDNA promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction91">
 <bp:evidence rdf:resource="#Evidence104" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CBX5 (HP-1alpha) binds TRIM28 (KAP1) in SUMO2-6K-TRIM28:KRAB-ZFP:retroelement chromatin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">B-WICH:histone acetyltransferase acetylates histone H3 at lysine-9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction94">
 <bp:evidence rdf:resource="#Evidence107" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KRAB-ZFP binds retroelement DNA in chromatin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction93">
 <bp:evidence rdf:resource="#Evidence106" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SETDB1 in ATF7IP:SETDB1:SUMO2-6K-TRIM28:KRAB-ZFP:retroelement trimethylates lysine-9 of histone H3 in nucleosomes</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction90">
 <bp:evidence rdf:resource="#Evidence101" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TDG excises 5-formylcytosine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction99">
 <bp:evidence rdf:resource="#Evidence113" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">me3-K16-ATF7IP:SETDB1 and MORC2 bind MPHOSPH8 (MPP8) in HUSH complex:L1 RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TASP1 cleaves KMT2B</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the MLL1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CBX3 (HP1gamma) binds histone H3 dimethylated at lysine-9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction96">
 <bp:evidence rdf:resource="#Evidence109" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRIM28 in TRIM28:KRAB-ZFP:retroelement chromatin autoSUMOylates with SUMO2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TTF-I binds to the Sal Box</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction95">
 <bp:evidence rdf:resource="#Evidence108" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRIM28 (KAP1) binds KRAB-ZFP in KRAB-ZFP:retroelement chromatin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of ERCC6 (CSB), EHMT2 (G9a), and NuRD to the promoter of rRNA gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction98">
 <bp:evidence rdf:resource="#Evidence112" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SETDB1 in me3-K16-ATF7IP:SETDB1:MORC2:HUSH complex:L1HS,L1PA2,3 heterochromatin trimethylates lysine-9 of histone H3 in adjacent nucleosome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TTF1:rRNA promoter:ERCC6:EHMT2 complex dimethylates histone H3 at lysine-9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction97">
 <bp:evidence rdf:resource="#Evidence110" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATF7IP:SETDB1 binds SUMO2-6K-TRIM28:KRAB-ZFP:retroelement chromatin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction81">
 <bp:evidence rdf:resource="#Evidence91" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DNMT3B:DNMT3L binds chromatin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction80">
 <bp:evidence rdf:resource="#Evidence90" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DNMT1 methylates cytosine in hemimethylated DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction83">
 <bp:evidence rdf:resource="#Evidence93" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DNMT3A:DNMT3L binds chromatin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction82">
 <bp:evidence rdf:resource="#Evidence92" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UHRF1 binds chromatin with hemimethylated cytosine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction89">
 <bp:evidence rdf:resource="#Evidence100" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TET1,2,3 oxidizes 5-hydroxymethylcytosine to 5-formylcytosine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction88">
 <bp:evidence rdf:resource="#Evidence99" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TET1,2,3 oxidizes 5-formylcytosine to 5-carboxylcytosine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction85">
 <bp:evidence rdf:resource="#Evidence95" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DNMT3B:DNMT3L methylates cytosine in DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction84">
 <bp:evidence rdf:resource="#Evidence94" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UHRF1:Chromatin binds DNMT1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction87">
 <bp:evidence rdf:resource="#Evidence98" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TET1,2,3 oxidizes 5-methylcytosine to 5-hydroxymethylcytosine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction86">
 <bp:evidence rdf:resource="#Evidence97" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TDG excises 5-carboxylcytosine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction70">
 <bp:evidence rdf:resource="#Evidence79" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDK4 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction72">
 <bp:evidence rdf:resource="#Evidence81" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPARG2 transcription is stimulated by PPARG2:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction71">
 <bp:evidence rdf:resource="#Evidence80" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ABL1 binds PPARG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction78">
 <bp:evidence rdf:resource="#Evidence87" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PAXIP1:PAGR1 complex, NCOA6 and KDM6A bind MLL3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep47" />
 <bp:pathwayOrder rdf:resource="#PathwayStep69" />
 <bp:pathwayOrder rdf:resource="#PathwayStep48" />
 <bp:pathwayOrder rdf:resource="#PathwayStep67" />
 <bp:pathwayOrder rdf:resource="#PathwayStep46" />
 <bp:pathwayOrder rdf:resource="#PathwayStep68" />
 <bp:pathwayOrder rdf:resource="#PathwayStep49" />
 <bp:pathwayOrder rdf:resource="#PathwayStep50" />
 <bp:pathwayOrder rdf:resource="#PathwayStep72" />
 <bp:pathwayOrder rdf:resource="#PathwayStep51" />
 <bp:pathwayOrder rdf:resource="#PathwayStep73" />
 <bp:pathwayOrder rdf:resource="#PathwayStep70" />
 <bp:pathwayOrder rdf:resource="#PathwayStep71" />
 <bp:pathwayOrder rdf:resource="#PathwayStep54" />
 <bp:pathwayOrder rdf:resource="#PathwayStep76" />
 <bp:pathwayOrder rdf:resource="#PathwayStep55" />
 <bp:pathwayOrder rdf:resource="#PathwayStep77" />
 <bp:pathwayOrder rdf:resource="#PathwayStep52" />
 <bp:pathwayOrder rdf:resource="#PathwayStep74" />
 <bp:pathwayOrder rdf:resource="#PathwayStep53" />
 <bp:pathwayOrder rdf:resource="#PathwayStep75" />
 <bp:pathwayOrder rdf:resource="#PathwayStep58" />
 <bp:pathwayOrder rdf:resource="#PathwayStep59" />
 <bp:pathwayOrder rdf:resource="#PathwayStep56" />
 <bp:pathwayOrder rdf:resource="#PathwayStep78" />
 <bp:pathwayOrder rdf:resource="#PathwayStep57" />
 <bp:pathwayOrder rdf:resource="#PathwayStep79" />
 <bp:pathwayOrder rdf:resource="#PathwayStep80" />
 <bp:pathwayOrder rdf:resource="#PathwayStep61" />
 <bp:pathwayOrder rdf:resource="#PathwayStep83" />
 <bp:pathwayOrder rdf:resource="#PathwayStep62" />
 <bp:pathwayOrder rdf:resource="#PathwayStep81" />
 <bp:pathwayOrder rdf:resource="#PathwayStep60" />
 <bp:pathwayOrder rdf:resource="#PathwayStep82" />
 <bp:pathwayOrder rdf:resource="#PathwayStep65" />
 <bp:pathwayOrder rdf:resource="#PathwayStep66" />
 <bp:pathwayOrder rdf:resource="#PathwayStep63" />
 <bp:pathwayOrder rdf:resource="#PathwayStep64" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction38" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction59" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction70" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction50" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction72" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction56" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction55" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction58" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction57" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction52" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction74" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction51" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction73" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction54" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction53" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction75" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction49" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction48" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction61" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction45" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction67" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction44" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction66" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction47" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction69" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction46" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction68" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction41" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction63" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction40" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction62" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction43" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction65" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction42" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction64" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence46" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The ligand-activated complex of a master transcription regulator of adipogenesis, nuclear receptor PPARG, and its partner, nuclear receptor RXRA, recruits MLL3 and MLL4 complexes to target gene loci, leading to establishment of activating epigenetic chromatin marks. The existing experimental evidence implies that MLL3-ASCOM and MLL4-ASCOM complexes are recruited to PPARG:RXRA-target loci, as described below.  PPARG isoform PPARG2-positive adipocyte nuclei isolated from visceral adipose tissue show significantly higher expression level of KMT2C, the catalytic subunit of the MLL3 complex, and PAXIP1, a cofactor of MLL3 and KMT2D (MLL4) complexes, than PPARG2-negative nuclei (Yu et al. 2016). Based on mouse studies, PAXIP1 (PTIP), an accessory subunit of MLL3 and MLL4 complexes, is required for adipogenesis in mouse embryonic fibroblasts (MEFs) and primary preadipocytes. PAXIP1-deficient MEFs show significant defects in both PPARG- and CEBPA-stimulated adipogenesis (Cho et al. 2009). Knockout of Paxip1 gene in brown adipose tissue (BAT) leads to significant decrease of BAT in knockout mice, and a significant decrease of expression of markers shared between white adipose tissue and BAT, such as Pparg, Cebpa, and Fabp4, as well as BAT-specific/prevalent markers Prdm16, Cidea, Mpzl2 (Eva1), Ntrk3, Ucp1, Ppargc1a (Pgc1a), Cox5b and Cox8b (Cho et al. 2009). Paxip1 BAT knockout mice are cold intolerant, with impaired cold-mediated induction of genes involved in fatty acid catabolism, such as Cpt1a, Lpl, and Mlycd (Mcd) (Cho et al. 2009).  In prostate cancer, KMT2D and PPARG are overexpressed at the protein level relative to the normal tissue (Zhai et al. 2022). KMT2D knockdown significantly reduces the lipid droplet content in prostate cancer cell lines (Zhai et al. 2022). In prostate cancer tumors, KMT2D mRNA expression significantly correlates with mRNA expression of lipid metabolism genes FASN, ACC, SCD, and ACLY (Zhai et al. 2022). KMT2D knockdown in prostate cancer cell lines leads to significant decrease in the mRNA levels of ACC, ACLY, and FASN (Zhai et al. 2022). Stimulation of PPARG by the synthetic agonist rosiglitazone stimulates lipid synthesis in prostate cancer cell lines, but the effect of rosiglitazone is diminished upon KMT2D knockdown (Zhai et al. 2022).  In addition to regulating genes involved in lipid metabolism, the PPARG:RXRA complex (Nielsen et al. 2008) and MLL3/MLL4 complexes (Jang et al. 2019: supplementary information) may also regulate expression of some of the genes involved in glucose metabolism and the tricarboxylic acid (TCA) cycle.  Hepatic steatosis represents the synthesis and accumulation of triglycerides in hepatocytes which can, if prolonged, lead to the development of non-alcoholic fatty liver disease (NAFLD) that can progress to non-alcoholic steatohepatitis (NASH), ultimately resulting in liver cirrhosis (Hardy et al. 2016). Like Kmt2c (Mll3) delta/delta mice, which express catalytically inactive Kmt2c (Lee, Saha et al. 2008; Lee S., Lee J. et al. 2008), Kmt2d (Mll4)+/- mice, with deletion of one allele of Kmt2d, are resistant to high fat diet-induced hepatic steatosis, with Kmt2d+/- livers accumulating much less fat relative to wild type littermate controls in response to high fat diet feeding (Kim et al. 2016). Bulk transcriptomic analysis of Kmt2d+/- mouse livers shows that the expression of a large portion of high fat diet controlled genes requires Kmt2d (Kim et al. 2016). Among the defined hepatic steatotic transcription factors, which include MLXIPL (ChREBP), SREBF1 (SREBP1) isoform SREBP1c (SREBP 1C), the liver X receptors (LXRs) &#8211; NR1H3 (LXRA) and NR1H2 (LXRB), and PPARG, KMT2D has been reported to associate with LXRs (Lee S., Lee J. et al. 2008) and PPARG (Lee, Saha et al. 2008). No association between mouse orthologs of KMT2D and MLXIPL or SREBP1c could be detected (Kim et al. 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction77">
 <bp:evidence rdf:resource="#Evidence86" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PAXIP1 binds PAGR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep45" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence45" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">During adipogenesis, the KMT2D (MLL4) complex preferentially localizes to active enhancers, marked by the presence of mono- or dimethylated histone H3 lysine-4 (H3K4me1/2, residue K4 corresponds to residue K5 in nascent histone H3), acetylated H3 lysine-27 (H3K27ac), and the presence of RNA Pol II. KMT2D localizes to these active enhancers together with the adipogenic transcription factors CEBPB, CEBPA, and PPARG, and is especially enriched at high confidence enhancers that are both CEBP and PPARG positive (Lee et al. 2013). Single Kmt2c (Mll3) knockout in mouse brown preadipocytes led to a modest decrease of H3K4me1, while double Kmt2c;Kmt2d (Mll4) knockout led to a global decrease of H3K4me1/2 (Lee et al. 2013). Most MLL4-binding sites are marked by both H3K4me1 and H3K4me2 during adipogenesis (Lee et al. 2013). Double knockout of Kmt2c and Kmt2d in differentiating mouse adipocytes prevented increase in H3K4me1/2, H3K27ac, Mediator complex and RNA Pol II on adipogenic enhancers, specifically on Cebpa and Pparg gene loci (Lee et al. 2013). KMT2D-dependent deposition of H3K4me1/2 marks was also detected on some adipogenic promoters, but was less pronounced than on adipogenic enhancers (Lee et al. 2013). Deletion of Kmt2d significantly decreased expression of genes associated with Kmt2d+ adipogenic enhancers (Lee et al. 2013). The expression of KMT2C, the catalytic subunit of the MLL3 complex, is upregulated during brown adipocyte differentiation (Son et al. 2016).  Transgenic mice that express catalytically inactive form of Kmt2c (Lee, Saha et al. 2008; Lee, Lee et al. 2008) or that have a heterozygous loss of Kmt2d (Kim et al. 2016) are resistant to fatty liver formation induced by high-fat diet. Expression of a large portion of high-fat diet induced genes in mouse liver requires Kmt2d (Kim et al. 2016). Among the defined transcription factors that promote high-fat diet-induced hepatic steatosis (ChREBP, SREBP1c, LXRs, and PPARG), ChREBP and SREBP1c do not interact with KMT2C/D (Kim et al. 2016).  Gomisin N, a lignin isolated from magnolia-vine (Schisandra chinensis) was shown to inhibit, without cytotoxic effects, differentiation of mouse 3T3-L1 preadipocytes by inhibiting mitotic clonal expansion during early adipogenesis (Jang et al. 2017). Gomisin N treatment reduces KMT2D but not KMT2C mRNA levels, and also reduces the mRNA level of adipogenic transcription factors CEBPB, CEBPA, and PPARG, as well as their targets FABP4 (aP2) and FASN (FAS), inhibiting lipid accumulation and formation of lipid droplets, both in 3T3-L1 preadipocytes and in adipose tissue of mice on high fat diet. Gomisin N ameliorates hepatic steatosis in obese mice on high fat diet (Jang et al. 2017).  The epigenomic reader BRD4, essential for both white and brown adipose tissue development but dispensable for adipose tissue maintenance, is enriched on active enhancers during the initial stages of adipogenesis and on promoters that associate with enhancers at terminal stages of adipogenesis (Lee et al. 2017). More than 90% of Brd4 genomic binding sites lose Brd4 in mouse preadipocytes that are double knockout for Kmt2c and Kmt2d (Lee et al. 2017). The majority of Brd4-bound enhancers are co-occupied by Kmt2d, Ep300, Cebpa or Cebpb, and Pparg (Lee et al. 2017). Brd4 knockout does not affect binding of Cebpb and Kmt2d to adipogenesis target genes nor does it affect deposition of activating epigenetic marks, H3K4me1 and H3K27ac, at these genes, but it reduces binding of transcriptional machinery (e.g. Med1, Tbp, RNA Pol II, Cdk9) and mRNA synthesis (Lee et al. 2017). Brd2 and Brd3 may be able to partially compensate for the loss of Brd4 (Lee et al. 2017). Inhibition of Brd proteins by synthetic inhibitor JQ1 inhibits expression of Pparg targets Cepba, Fabp4 and Adipoq induced by rosiglitazone, a synthetic Pparg agonist (Lee et al. 2017). Brd4 was shown to physically associate with Cebpb (Lee et al. 2017). Conditional knockout mice in which Brd4 gene is deleted in progenitor cells of brown adipose tissue and muscle lineages die immediately after birth because of breathing impairment, exhibiting severe reduction in muscle mass and brown adipose tissue (Lee et al. 2017).  Based on mouse studies, at the onset of white and brown adipogenesis the accessory subunit of MLL3 and MLL4 complexes, PAGR1 (also known as PA1) is needed for induction of CEBPB and CEBPD transcription factors (Lee et al. 2020). Based on a study in immortalized mouse brown adipocytes, PAGR1 is recruited to the CEBPB gene promoter by activated CREB1, which is phosphorylated at serine residue S133 (p-S133-CREB1) (Lee et al. 2020). Based on a study in mouse white preadipocyte cell line 3T3-L1, PAGR1 is recruited to CEBPD gene promoter by ligand-activated glucocorticoid receptor (GR) (Lee et al. 2020).  Based on a study conducted using the mouse 3T3-L1 white preadipocyte cell line as a model system, dehydroleucodine, a sesquiterpene lactone isolated from Artemisia douglasiana (California mugwort) halts mitotic clonal expansion at the initiation of white adipogenesis (Abood et al. 2017). Dehydroleucodine decreases the phosphorylation of ERKs and AKT, as well as levels of CCNA, CCND, CDK2, and CDK4, while increasing the level of p27 (CDKN1B), resulting in G0/G1 cell cycle arrest of mouse white preadipocytes (Abood et al. 2017). Dehydroleucodine also downregulates JMJD2B and KMT2D, leading to downregulation of CEBPB and PPARG, respectively (Abood et al. 2017).  Expression of the histone 3 mutant H3.3 K4M in mouse brown preadipocytes impairs adipose tissue development, but when H3.3 K4M is expressed in already differentiated mouse brown adipocytes, the maintenance and thermogenic function of brown adipose tissue are not affected (Jang et al. 2019). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep84" />
 <bp:pathwayOrder rdf:resource="#PathwayStep44" />
 <bp:pathwayOrder rdf:resource="#PathwayStep85" />
 <bp:pathwayOrder rdf:resource="#PathwayStep86" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction78" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction77" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction76" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence44" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Epigenetic regulation of gene expression by MLL3 and MLL4 complexes</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The KMT2C (MLL3) complex, together with the related KMT2D (MLL4) complex, is most similar to Drosophila Trr (Trithorax-related) and mediates hitone H3 lysine-4 (H3K4 - lysine 5 in nascent histone H3) monomethylation, with the establishment of the H3K4me1 epigenetic marks, at transcription enhancers throughout the human genome (For review, please refer to Hu et al. 2013, Piunti and Shilatifard 2016, Klonou et al. 2021).  The MLL3 and MLL4 complexes monomethylate H3K4 at transcription enhancers throughout the human genome, with estimates ranging from approximately 12,000 to over 20,000 sites, depending on the cell type and developmental stage. Full activation of gene expression through MLL3 and MLL4 complex target enhancers appears to require simultaneous monomethylation of H3K4 by MLL3 and/or MLL4 complexes, and acetylation of H3K27 by the histone acetyltransferase p300/CBP, recruited to enhancers through direct interactions with the MLL3 and MLL4 complexes. KDM6A (also known as UTX), a lysine demethylase that acts as an accessory subunit of MLL3 and MLL4 complexes, facilitates H3K27 acetylation by removing inhibitory methyl groups from H3K27, deposited by the Polycomb repressor PRC2 complex (reviewed in Fagan and Dingwall 2019).  KMT2C (also known as MLL3), the catalytic subunit of the MLL3 complex, contains two closely related plant homeodomain (PHD) zinc finger clusters, with 6-7 zinc fingers, in the N-terminal region, and a single PHD zinc finger near the C-terminus, which are involved in protein-protein interactions. The HMG domain in KMT2C enables DNA binding, while the SET domain provides catalytic activity. KMT2C possesses multiple nuclear receptor (NR) interaction motifs (LLXXL or LXXLL), which are important for recruitment of the MLL3 complex to NR-regulated enhancers (reviewed in Fagan and Dingwall 2019).  While H3K4 monomethylation by MLL3 and MLL4 complexes may not be essential for expression of developmental genes, it is likely important for fine tuning of transcription levels and timing, both during normal development and in cancer. Although a broad dispersion of cancer mutations in the coding regions of the KMT2C and KMT2D genes, as well as the presence of many truncating mutations, imply a tumor suppressor role, activating mutations in the SET domains have also been reported, suggesting that a tumor suppressive vs. oncogenic role is context-dependent (reviewed in Fagan and Dingwall 2019).  KMT2C is frequently mutated in cancer. KMT2C may be important for driving hormone-stimulated proliferation of breast cancer cells that are ESR1-positive and ERBB2-negative. In mice, simultaneous overexpression of Pik3ca and inactivation of the Kmt2c blocks differentiation of the mammary gland and leads to increased stem cell self-renewal through HIF pathway activation (reviewed in Fagan and Dingwall 2019).  Non-small cell lung cancer (NSCLC) is characterized by frequent co-occurrence of mutations in KMT2C and KMT2D (also known as MLL4, the catalytic subunit of the MLL4 complex) (reviewed in Fagan and Dingwall 2019).  DNA damage-induced transcription of TP53 target genes requires both KMT2C and KMT2D. KMT2C is also implicated in TP53-dependent DNA double strand break repair in a transcription-independent manner. KTM2C and KMT2D contribute to maintenance of epithelial cell states by negatively regulating the epithelial-to-mesenchymal transition. KMT2C mutations in lung and breast cancer are frequently found in the first PHD that is involved in the interaction with the BAP1 histone deubiquitinating complex, linked to Polycomb repressor complex-dependent gene silencing (reviewed in Fagan and Dingwall 2019).  Heterozygous germline LOF mutations in KTM2C are associated with Kleefstra syndrome-2 and autism spectrum disorder (reviewed in Fagan and Dingwall 2019).  In mouse, Kmt2c and Kmt2d are implicated in enhancer priming and de novo enhancer activation during embryonic development. This function is not essential for the maintenance of cell identity and self-renewal of embryonic stem cells (ESCs) and somatic cells but is necessary for ESC reprogramming during differentiation and for production of induced pluripotent stem cells (iPSCs) (reviewed in Fagan and Dingwall 2019).   Knockout of KMT2D, the catalytic subunit of the MLL4 complex, in human colon carcinoma cell line HCT116, which already harbors inactivating mutations in both alleles of KMT2C (the catalytic subunit of the MLL3 complex), leads to significant global reduction of H3K4 monomethylation (Hu et al. 2013). Knockout studies of KMT2C and KMT2D in HCT116 cells and mouse embryonic fibroblasts (MEFs) implicate at least partially redundant roles of MLL3 and MLL4 complexes in H3K4 monomethylation (Hu et al. 2013). Genome-wide ChIP-seq analysis in both HCT116 cells and MEFs showed that ~80% of the MLL4 peaks are enriched at intergenic and intragenic regions, while only ~20% of the peaks map to transcription start sites (TSS) (Hu et al. 2013). MLL4 binding sites at SAE1 and AP3B1 gene loci in HCT116 cells, and at Nanog and Lefty1 loci in MEFs, are co-occupied by enhancer region markers H3K4me1, EP300, and acetylated H3K27 (Hu et al. 2013). Many of the genes associated with MLL3/MLL4-bound enhancers in HCT116 cells are implicated in intracellular signaling, while genes associated with MLL3/MLL4-independent enhancers tend to be implicated in regulation of gene expression (Hu et al. 2013).  HOXA9, encoded by a target gene of KMT2A (MLL1) and KMT2B (MLL2) complexes, may function as a pioneer factor at de novo enhancers in acute myeloid leukemia (AML) and recruit CEBPA and the MLL3 and MLL4 complexes to enhancers of leukemogenesis-promoting genes (Sun et al. 2018).  KMT2D is frequently mutated in cancer (reviewed in Dhar and Lee 2021) and is one of the most frequently mutated genes in non-Hodgkin lymphoma, such as follicular lymphoma and diffuse large B cell lymphoma, where loss-of-function (LOF) of KMT2D appears to be an early event that cooperates with the over-expression of the BCL2 oncogene. Knockout of Kmt2d in mouse B cell progenitors impairs their differentiation and promotes lymphoma development. KMT2D LOF in lymphoma is associated with reduced H3K4me1 mark at enhancers of multiple tumor suppressor genes (reviewed in Fagan and Dingwall 2019).  KMT2D chromatin enrichment sites significantly overlap with TP53 binding sites. Aberrant transcription associated with TP53 mutations in colon carcinoma is dependent on KMT2D-mediated H3K4 monomethylation. KMT2D can be inactivated through phosphorylation by SGK1, a PI3K effector kinase closely related to AKT1. SGK1 is the estrogen-inducible kinase, whose transcription is collaboratively activated by ESR1 and KMT2D. SGK1-mediated phosphorylation on KMT2D on serine S1331 near the second PHD results in downregulation of H3K4 monomethylation at ESR1-target genes, thus constituting a negative feedback loop (reviewed in Fagan and Dingwall 2019).  Heterozygous germline LOF mutations in KMT2D are associated with Kabuki syndrome-1. Kabuki syndrome patients have a modestly increased predisposition to cancer, in particular lymphoma, Wilms tumor, hepatoblastoma, synovial sarcoma and neuroblastoma. Mice with brain-specific knockout of Kmt2d (Mll4) develop medulloblastoma that shows hyperactivation of Ras and Notch signaling (reviewed in Fagan and Dingwall 2019).  Based on mouse studies, MLL3 and MLL4 complexes play an important role in adipogenesis and myogenesis. Kmt2c KO mice die around birth with no obvious morphological abnormalities in embryonic development, while Kmt2d KO mice show early embryonic lethality around E9.5 (Lee et al. 2013). Pups with Kmt2d KO in precursors of brown preadipocytes and skeletal myocytes are obtained at the expected Mendelian ratio but display marked reduction in back muscles and die immediately after birth due to breathing malfunction, also showing a decrease in brown adipose tissue mass (Lee et al. 2013). In cultured mouse brown preadipocytes, KO of Kmt2d leads to a moderate differentiation defect along with a transient up-regulation of Kmt2c expression, whereas KO of Kmt2c has no effect on adipogenesis, suggesting a more prominent role of KMT2D in development and a partial compensation of KMT2D loss by KMT2C (Lee et al. 2013). KO of Kmt2d 3T3-L1 mouse white preadipocytes inhibits adipogenesis, and Kmt2c and Kmt2d are also required for adipogenesis in mouse embryonic fibroblasts (Lee et al. 2013). By ChIP-seq, the average length of Kmt2d binding regions is between 350 and 400 bp, and the binding regions change dramatically from the preadipocytes stage to the onset of adipogenesis, but are then Kmt2d-binding regions were largely non-overlapping between brown adipocytes and skeletal myocytes (Lee et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction79">
 <bp:evidence rdf:resource="#Evidence89" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DNMT3A:DNMT3L methylates cytosine in DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayOrder rdf:resource="#PathwayStep32" />
 <bp:pathwayOrder rdf:resource="#PathwayStep33" />
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep36" />
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayOrder rdf:resource="#PathwayStep37" />
 <bp:pathwayOrder rdf:resource="#PathwayStep34" />
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayOrder rdf:resource="#PathwayStep35" />
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayOrder rdf:resource="#PathwayStep38" />
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayOrder rdf:resource="#PathwayStep39" />
 <bp:pathwayOrder rdf:resource="#PathwayStep40" />
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep41" />
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep42" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction37" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction34" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction33" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction36" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction30" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction32" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction26" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction22" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction24" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction20" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of WDR5-containing histone-modifying complexes</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">WDR5 is a component of six mammalian histone methyltransferase KMT2 complexes: Mixed Lineage Leukemia (MLL) 1-4, SET1A, and SET1B. All KMT2 complexes consist of a histone methyltransferase (KMT2A, KMT2B, KMT2C, KMT2D, SETD1A, or SETD1B, respectively) and the WRAD subcomplex composed of WDR5, RBBP5, ASH2L, and DPY30. The WRAD complex regulates the enzymatic activity of histone methyltransferases and enables their recruitment to chromatin. Additional transcription cofactors associate with each KMT2 histone methyltransferase complex, enabling their functional diversification. For a detailed overview, please refer to Cho et al. 2007, Song and Kingston 2008, Takahashi et al. 2011, Couture and Skiniotis 2013, van Nuland et al. 2013, Klonou et al. 2021.  The KMT2 complexes are evolutionarily conserved. While a single SET1/COMPASS complex is present in yeast, three distinct complexes are present in Drosophila: trithorax (Trx), trithorax-related (Trr), and Set1. In mammals, due to gene duplication, two Trx-like complexes (one with KMT2A and another with KMT2B as the catalytic subunit), as well as two Trr-like complexes (one with KMT2C and another with KMT2D as the catalytic subunit), and two Set1-like complexes (one with SETD1A and another with SETD1B as the catalytic subunit) are formed. For review, please refer to Rao and Dou 2015.  All KMT2 complexes methylate lysine K5 of histone H3 (K4 in mature histone H3 peptides, as the initiator methionine is removed), which is associated with transcriptional activation. Different KMT2 complexes preferentially monomethylate, dimethylate, or trimethylate H3K4, depending on the presence of accessory subunits, transcriptional co-factors, and posttranslational modifications. The catalytic activity of KMT2 complexes may differ between endogenous complexes and complexes reconstituted in vitro by mammalian proteins expressed and produced in bacterial or insect cells. The KMT2A and KMT2B complexes preferentially methylate H3K4 at a limited number of target gene promoters, while KMT2C and KMT2D complexes preferentially methylate H3K4 at a limited number of target gene enhancers. SETD1A and SETD1B complexes are responsible for the bulk of cellular H3K4 methylation and show less target specificity. For overview, please refer to Patel et al. 2009, Wang et al. 2009, Rao and Dou 2015.  In both Drosophila and vertebrates, KMT2 complexes control the expression of evolutionarily conserved Hox genes which serve as master regulators of embryonic patterning (reviewed in Soshnikova and Duboule 2009).  Germline mutations in human KMT2 complexes are the underlying cause of several chromatinopathies. Germline loss-of-function (LOF) mutations in KMT2A cause Weideman-Steiner syndrome, a rare autosomal-dominant disorder characterized by intellectual disability, developmental delay, pre- and post-natal growth delay, hypertrichosis, short stature, hypotonia, distinctive facial features, skeletal abnormalities, feeding problems and behavioral difficulties (reviewed in Castiglioni et al. 2022). Germline LOF mutations in KMT2B cause dystonia-28 (DYT28) and intellectual developmental, autosomal dominant disorder-68 (MRD68). DYT28 is an autosomal dominant neurologic disorder characterized by onset of progressive dystonia in the first decade of life (reviewed in Zech et al. 2019), while MRD68 is an autosomal dominant disorder characterized by developmental delay/intellectual disability, microcephaly, poor growth, feeding difficulties, and dysmorphic features (Cif et al. 2020). Germline LOF mutations in KMT2C cause Kleefstra syndrome-2 (KLEFS2), an autosomal dominant neurodevelopmental disorder characterized by delayed psychomotor development, variable intellectual disability, and mild dysmorphic features (reviewed in Lavery et al. 2020). Germline LOF mutations in KMT2D cause Kabuki syndrome 1, a congenital mental retardation syndrome with postnatal dwarfism, a facial dysmorphism and skeletal abnormalities (reviewed in Lavery et al. 2020). Germline LOF mutations in SETD1A cause early-onset epilepsy with or without developmental delay (EPEDD), an autosomal dominant neurologic disorder (Yu et al. 2019), and neurodevelopmental disorder with speech impairment and dysmorphic facies (NEDSID) (Kummeling et al. 2021). Germline LOF mutations in SETD1B cause intellectual developmental disorder with seizures and language delay (IDDSELD) (Roston et al. 2021).  Somatic mutations in KMT2 genes contribute to cancer development. They were first discovered in Mixed Lineage Leukemia (MLL), characterized by chromosomal translocations that involve the KMT2A gene locus on chromosome 11 (chromosomal band 11q23) and result in the expression of fusion proteins with oncogenic properties. Besides gene fusions, other types of KMT2A mutations are also present in blood cancers (most frequently in high-grade B-cell lymphoma, T-cell lymphoblastic leukemia, and acute myeloid leukemia) and solid tumors (most often reported in lung adenocarcinoma, colon adenocarcinoma, and bladder urothelial carcinoma). Somatic cancer mutations in other KMT2 genes (KMT2B, KMT2C, KMT2D, SETD1A and SETD1B) are less characterized but most frequently affect the catalytic SET domain and show different distributions between different cancer types. For review, please refer to Rao and Dou 2015, Castiglioni et al. 2022. Several anti-cancer therapeutics are being developed that affect the association of KMT2 enzymes with components of the WRAD complex, in particular WDR5 (reviewed in Vedadi et al. 2017; Siladi et al. 2022).  WDR5 is also a component of three histone acetyltransferase complexes, GCN5-ATAC, PCAF-ATAC, and MOF/KAT8-NSL. The role of WDR5 in epigenetic regulation of gene expression through histone acetylation is under investigation (reviewed in Guarnaccia and Tansey 2018).  The function of WDR5-containing histone modifying complexes is currently depicted in the following Reactome pathways: &quot;Transcriptional regulation of granulopoiesis&quot; (MLL1 complex), &quot;Transcriptional regulation by RUNX1&quot; (MLL1 complex), &quot;Activation of anterior HOX genes in hindbrain development during early embryogenesis&quot; (MLL3 complex and MLL4 complex), &quot;TCF dependent signaling in response to WNT&quot; (MLL4 complex), and &quot;Chromatin organization&quot; (MLL1 complex, MLL2 complex, MLL3 complex, MLL4 complex, SET1A complex, SET1B complex, GCN5-ATAC complex, PCAF-ATAC complex, and MOF/KAT8-NSL complex). Please note that there is an inconsistency in naming of MLL2 and MLL4 complexes in the literature and in Reactome pathways, as MLL2 and MLL4 have been used as synonyms for both KMT2B and KMT2D, depending on whether the numbering of MLLs referred to order of cloning or whether it referred to similarity to founding MLL1 (MLL, KMT2A) enzyme. The current UniProt standard is for MLL2 to be used as the preferred synonym of KMT2B, and for MLL4 to be used as the preferred synonym of KMT2D. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction74">
 <bp:evidence rdf:resource="#Evidence83" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unliganded PPARG:RXRA heterodimer recruits corepressors to target gene loci</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayOrder rdf:resource="#PathwayStep43" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Epigenetic regulation by WDR5-containing histone modifying complexes</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string"> WDR5 is a component of six histone methyltransferases and three histone acetyltransferases involved in epigenetic regulation of gene expression (reviewed in Guarnaccia and Tansey 2018).  The WDR5 histone methyltransferase complexes (KMT2 complexes) include the Mixed Lineage Leukemia (MLL) 1-4, SET1A, and SET1B. All KMT2 complexes consist of a histone methyltransferase (KMT2A, KMT2B, KMT2C, KMT2D, SETD1A, or SETD1B, respectively) and the WRAD subcomplex composed of WDR5, RBBP5, ASH2L, and DPY30. The WRAD complex regulates the enzymatic activity of histone methyltransferases and enables their recruitment to chromatin. Additional transcription cofactors associate with each KMT2 histone methyltransferase complex, enabling their functional diversification. All KMT2 complexes methylate lysine K5 of histone H3 (K4 in mature histone H3 peptides, as the initiator methionine is removed), which is associated with transcriptional activation. Different KMT2 complexes preferentially monomethylate, dimethylate, or trimethylate H3K4, depending on the presence of accessory subunits, transcriptional co-factors, and posttranslational modifications. The KMT2A and KMT2B complexes preferentially methylate H3K4 at a limited number of target gene promoters, while KMT2C and KMT2D complexes preferentially methylate H3K4 at a limited number of target gene enhancers. SETD1A and SETD1B complexes are responsible for the bulk of cellular H3K4 methylation and show less target specificity. For a detailed overview, please refer to Cho et al. 2007, Song and Kingston 2008, Patel et al. 2009, Wang et al. 2009, Takahashi et al. 2011, Couture and Skiniotis 2013, van Nuland et al. 2013, Rao and Dou 2015, Klonou et al. 2021.  WDR5 is also a component of three histone acetyltransferase complexes, GCN5-ATAC, PCAF-ATAC, and MOF/KAT8-NSL. The role of WDR5 in epigenetic regulation of gene expression through histone acetylation is under investigation (reviewed in Guarnaccia and Tansey 2018).  The KMT2C (MLL3) complex, together with the related KMT2D (MLL4) complex, is most similar to Drosophila Trr (Trithorax-related) and mediates hitone H3 lysine-4 (H3K4 - lysine 5 in nascent histone H3) monomethylation, with the establishment of the H3K4me1 epigenetic marks, at transcription enhancers throughout the human genome, with estimates ranging from approximately 12,000 to over 20,000 sites, depending on the cell type and developmental stage. While H3K4 monomethylation by MLL3 and MLL4 complexes may not be essential for expression of developmental genes, it is likely important for fine tuning of transcription levels and timing, both during normal development and in cancer. For review, please refer to Hu et al. 2013, Piunti and Shilatifard 2016, Fagan and Dingwall 2019, and Klonou et al. 2021.  Based on mouse studies, MLL3 and MLL4 complexes play an important role in adipogenesis and myogenesis. During adipogenesis, the KMT2D (MLL4) complex preferentially localizes to active enhancers, marked by the presence of mono- or dimethylated histone H3 lysine-4 (H3K4me1/2, residue K4 corresponds to residue K5 in nascent histone H3), acetylated H3 lysine-27 (H3K27ac), and the presence of RNA Pol II. KMT2D localizes to these active enhancers together with the adipogenic transcription factors CEBPB, CEBPA, and PPARG, and is especially enriched at high confidence enhancers that are both CEBP and PPARG positive (Lee et al. 2013). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction73">
 <bp:evidence rdf:resource="#Evidence82" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Corepressors are released from liganded PPARG:RXRA heterodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">About half of the rRNA genes in the genome are actively expressed, being transcribed by RNA polymerase I (reviewed in Nemeth and Langst 2008, Bartova et al. 2010, Goodfellow and Zomerdijk 2012, Grummt and Langst 2013). As inferred from mouse, those genes that are expressed are activated by ERCC6 (also known as Cockayne Syndrome protein, CSB) which interacts with TTF-I bound to the T0 terminator region (also know as the Sal Box) of rRNA genes (Yuan et al. 2007, reviewed in Birch and Zomerdijk 2008, Grummt and Langst 2013). ERCC6 recruits the histone methyltransferase EHMT2 (also known as G9a) which dimethylates histone H3 at lysine-9 in the coding region of rRNA genes. The dimethylated lysine is bound by CBX3 (also known as Heterochromatic Protein-1gamma, HP1gamma) and increases expression of the rRNA gene. Continuing dimethylation depends on continuing transcription. Mutations in CSB result in dysregulation of RNA polymerase I transcription, which plays a role in the symptoms of Cockayne Syndrome (reviewed in Hannan et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction76">
 <bp:evidence rdf:resource="#Evidence85" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PAXIP1:PAGR1 complex, NCOA6 and KDM6A bind MLL4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">B-WICH complex positively regulates rRNA expression</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The B-WICH complex is a large 3 Mdalton complex containing SMARCA5 (SNF2H), BAZ1B (WSTF), ERCC6 (CSB), MYO1C (Nuclear myosin 1c), SF3B1, DEK, MYBBP1A, and DDX21 (Cavellan et al. 2006, Percipalle et al. 2006, Vintermist et al. 2001, Sarshad et al. 2013, Shen et al. 2013, reviewed in Percipalle and Farrants 2006). B-WICH is found at active rRNA genes as well as at 5S rRNA and 7SL RNA genes. B-WICH appears to remodel chromatin and recruit histone acetyltransferases that modify histones to transcriptionally active states.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction75">
 <bp:evidence rdf:resource="#Evidence84" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPARG binds RXRA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep89" />
 <bp:pathwayOrder rdf:resource="#PathwayStep90" />
 <bp:pathwayOrder rdf:resource="#PathwayStep91" />
 <bp:pathwayOrder rdf:resource="#PathwayStep94" />
 <bp:pathwayOrder rdf:resource="#PathwayStep92" />
 <bp:pathwayOrder rdf:resource="#PathwayStep93" />
 <bp:pathwayOrder rdf:resource="#PathwayStep88" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction81" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction80" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction83" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction82" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction79" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction85" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction84" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence88" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DNA methylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Methylation of cytosine is catalyzed by a family of DNA methyltransferases (DNMTs): DNMT1, DNMT3A, and DNMT3B transfer methyl groups from S-adenosylmethionine to cytosine, producing 5-methylcytosine and homocysteine (reviewed in Klose and Bird 2006, Ooi et al. 2009, Jurkowska et al. 2011, Moore et al. 2013). (DNMT2 appears to methylate RNA rather than DNA.) DNMT1, the first enzyme discovered, preferentially methylates hemimethylated CG motifs that are produced by replication (template strand methylated, synthesized strand unmethylated). Thus it maintains existing methylation through cell division. DNMT3A and DNMT3B catalyze de novo methylation at unmethylated sites that include both CG dinucleotides and non-CG motifs. DNA from adult humans contains about 0.76 to 1.00 mole percent 5-methylcytosine (Ehrlich et al. 1982, reviewed in Klose and Bird 2006, Ooi et al. 2009, Moore et al. 2013). Methylation of DNA occurs at cytosines that are mainly located in CG dinucleotides. CG dinucleotides are unevenly distributed in the genome. Promoter regions tend to have a high CG-content, forming so-called CG-islands (CGIs), while the CG-content in the remaining part of the genome is much lower. CGIs tend to be unmethylated, while the majority of CGs outside CGIs are methylated. Methylation in promoters and first exons tends to repress transcription while methylation in gene bodies (regions of genes downstream of the promoter and first exon) correlates with transcription (reviewed in Ehrlich and Lacey 2013, Kulis et al. 2013). Proteins such as MeCP2 and MBDs specifically bind 5-methylcytosine and may recruit other factors. Mammalian development has two major episodes of genome-wide demethylation and remethylation (reviewed in Zhou 2012, Guibert and Weber 2013, Hackett and Surani 2013, Dean 2014). In mice about 1 day after fertilization the paternal genome is actively demethylated by TET proteins together with thymine DNA glycosylase and the maternal genome is demethylated by passive dilution during replication, however methylation at imprinted sites is maintained. The genome has its lowest methylation level about 3.5 days post-fertilization. Remethylation occurs by 6.5 days post-fertilization. The second demethylation-remethylation event occurs in primordial germ cells of the developing embryo about 12.5 days post-fertilization. DNMT3A and DNMT3B, together with the non-catalytic DNMT3L, play major roles in the remethylation events (reviewed in Chen and Chan 2014). How the methyltransferases are directed to particular regions of the genome remains an area of active research. The mechanisms at each locus may differ in detail but a connection between histone modifications and DNA methylation has been observed (reviewed in Rose and Klose 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep100" />
 <bp:pathwayOrder rdf:resource="#PathwayStep98" />
 <bp:pathwayOrder rdf:resource="#PathwayStep99" />
 <bp:pathwayOrder rdf:resource="#PathwayStep96" />
 <bp:pathwayOrder rdf:resource="#PathwayStep97" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction90" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction89" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction88" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction87" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction86" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence96" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TET1,2,3 and TDG demethylate DNA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">About 2-6% of all cytosine residues and 70-80% of cytosine residues in CG dinucleotides in mammalian cells are methylated at the 5 position of the pyrimidine ring. The cytosine residues are methylated by DNA methyltransferases after DNA replication and can be demethylated by passive dilution during subsequent replication or by active modification of the 5-methylcytosine base. Cytosine demethylation is developmentally regulated: one wave of demethylation occurs in primordial germ cells and one wave occurs by active demethylation in the male pronucleus after fertilization. Some mechanisms of active demethylation remain controversial, however progressive oxidation of the methyl group of 5-methylcytosine followed by base excision by thymine DNA glycosylase (TDG) has been reproducibly demonstrated in vivo (reviewed in Wu and Zhang 2011, Franchini et al 2012, Cadet and Wagner 2013, Kohli and Zhang 2013, Ponnaluri et al. 2013, Rasmussen and Helin 2016). Ten-eleven translocation proteins TET1, TET2, and TET3 are dioxygenases that first oxidize 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC) (Tahiliani et al. 2009, Ito et al. 2010), which is found in significant quantities and specific genomic locations in stem cells and neurons (Kinney and Pradhan 2013). TET proteins can further oxidize 5-hmC to 5-formylcytosine (5-fC) and then 5-carboxylcytosine (5-caC) (He et al. 2011, Ito et al. 2011). G:5-fC and G:5-caC base pairs are recognized by TDG, which excises the 5-fC or 5-caC and leaves an abasic site. TET1 in mouse is expressed in neurons and its expression depends on neuronal activity (Guo et al. 2011, Kaas et al. 2013, Zhang et al. 2013). TET1 is also found in embryonic stem cells (Ficz et al. 2011, Koh et al. 2011, Wu et al. 2011) and in primordial germ cells of mice, where it plays a role in erasure of imprinting (Yamaguchi et al. 2013). TET3 is expressed in oocytes and zygotes of mice and is required for demethylation in the male pronucleus (Gu et al. 2011, Iqbal et al. 2011). TET2 is the most highly expressed TET family protein in hemopoietic stem cells and appears to act as a tumor suppressor. TET2 is also expressed in embryonic stem cells (Koh et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction61">
 <bp:evidence rdf:resource="#Evidence70" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLIN1 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction60">
 <bp:evidence rdf:resource="#Evidence69" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPARG binds ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway14">
 <bp:pathwayOrder rdf:resource="#PathwayStep111" />
 <bp:pathwayOrder rdf:resource="#PathwayStep112" />
 <bp:pathwayOrder rdf:resource="#PathwayStep113" />
 <bp:pathwayOrder rdf:resource="#PathwayStep114" />
 <bp:pathwayOrder rdf:resource="#PathwayStep115" />
 <bp:pathwayOrder rdf:resource="#PathwayStep116" />
 <bp:pathwayOrder rdf:resource="#PathwayStep117" />
 <bp:pathwayOrder rdf:resource="#PathwayStep118" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction105" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction103" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction104" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction101" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction99" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction102" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction100" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction98" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence111" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Human Silencing Hub (HUSH) complex comprises MPHOSPH8 (MPP8), Periphilin (PHPLN1), and TASOR, which appears to act as a scaffold that binds the other subunits (reviewed in Seczynska and Lehner 2023). The HUSH complex preferentially represses transcription of young LINE1 retroelements (Liu et al. 2018, Robbez-Masson et al. 2018) and some HIV integrants (Tchasovnikarova et al. 2015, Zhu et al. 2018, Chougui and Margottin-Goguet 2019). The HUSH complex creates repressive chromatin in two ways (reviewed in Seczynska and Lehner 2023). Firstly, HUSH can cause spreading of existing heterochromatin by binding existing trimethylated H3K9 and recruiting SETDB1 to trimethylate H3K9 of adjacent nucleosomes (Tchasovnikarova et al. 2015). Secondly, HUSH can initiate heterochromatin by binding nascent transcripts via its PHPLN1 subunit and recruiting SETDB1 to trimethylate lysine-9 of histone H3 (H3K9) at the locus being transcribed (Seczynska et al. 2022). By an uncharacterized mechanism, the HUSH complex targets long intronless cDNAs, such as those produced by retroelements, as well as unusually long exons of normal cellular genes (Seczynska et al. 2022). Introns somehow protect against silencing by HUSH, though actual splicing is not required (Seczynska et al. 2022). In mice, ZNF638 (NP220, Znf638 gene) recruits the HUSH complex to unintegrated murine leukemia virus (MLV) (Zhu et al. 2018) and in human cells ZNF638 (NP220) and HUSH silence recombinant adeno-associated viruses (Das et al. 2022). The potential recruitment of HUSH by ZNF638 to human retroelements is not yet demonstrated.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway15">
 <bp:pathwayOrder rdf:resource="#PathwayStep120" />
 <bp:pathwayOrder rdf:resource="#PathwayStep121" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction107" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction106" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence120" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PIWI-interacting RNAs (piRNAs) are short RNAs of 24-31 nucleotides that are produced by cleavage of longer RNAs and amplification by a &quot;ping-pong&quot; mechanism involving rounds of strand hybridization and cleavage (reviewed in Sun et al. 2022). The piRNAs are loaded onto PIWI proteins (PIWIL1, PIWIL2, PIWIL4) that are then guided by base-pairing of the piRNAs to nascent and mature transcripts, where the PIWI:piRNA complexes initiate transcriptional and post-transcriptional silencing, respectively (reviewed in Czech et al. 2018, Onishi et al. 2021, Wang et al. 2023). In mice, sources of piRNAs include transposon RNAs, long non-coding RNAs, exon transcripts, and RNAs from unannotated regions of the genome (Aravin et al. 2007, 2008). Two populations of piRNAs are observed during mouse development: pre-pachytene piRNAs and pachytene piRNAs (Aravin et al. 2008, Gan et al. 2011). Pre-pachytene piRNAs are present prenatally in prospermatogonial cells and postnatally in spermatogonial cells. Pachytene piRNAs are present in more mature postnatal spermatocytes and spermatids. The piRNAs derived from retroelements comprise about half (Aravin et al. 2008) or less (Gan et al. 2011) of the total pre-pachytene piRNAs and the portion falls sharply from pre-pachytene to pachytene (Gan et al. 2011). In mice, PIWIL2 (MILI, Piwil2 gene) is first detected in primordial germ cells that have reached the genital ridge and expression persists through meiosis in adults. PIWIL4 (MIWI2, PIWIl4 gene) is present in mouse germ cells during de novo DNA methylation shortly before and after birth. PIWIL1 (MIWI, PIWIL1 gene) is present during later stages of meiosis after birth (Aravin et al. 2008). PIWIL4 and PIWIL2 participate in re-methylation of the genome in mouse germ cells and consequent repression of transposable elements (Carmell et al. 2007, Aravin et al. 2008, Kuramochi-Miyagawa et al. 2008, Zoch et al. 2020). In mice, the piRNAs bound by PIWIL4 bind nascent transcripts of transposable elements and connects to the de novo DNA methylation machinery via SPOCD1 and C19ORF84 to direct DNA methylation to the transposable elements (Zoch et al. 2020, 2024). Mutations in SPOCD1 are associated with infertility in men (Zoch et al. 2024)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep110" />
 <bp:pathwayOrder rdf:resource="#PathwayStep102" />
 <bp:pathwayOrder rdf:resource="#PathwayStep119" />
 <bp:pathwayComponent rdf:resource="#Pathway14" />
 <bp:pathwayComponent rdf:resource="#Pathway15" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence102" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of endogenous retroelements</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transposable elements (TEs) constitute about 48.34% of the human genome (Osmanski et al. 2023) and can be classified by their transposition mechanisms: DNA transposons (about 3% of the human genome) transpose by excising a DNA intermediate and inserting it into a new location; retrotransposons (about 33% of the human genome) transpose by transcribing an element, reverse transcribing the RNA to DNA, and inserting the DNA copy into a new location. Retrotransposons can be divided into those that contain long terminal repeats (LTRs) and those that lack LTRs. Retrotransposons that contain LTRs are believed to be remnants of retroviruses, are therefore called endogenous retroviruses, and constitute about 9.45% of the human genome (Lander et al. 2001, Osmanski et al. 2023). No endogenous retroviruses are known to be currently transpositionally active in humans, with the most recent transpositions estimated to have occurred about 0.67 million years ago (Wildschutte et al. 2016). Retrotransposons that lack LTRs constitute about 34% of the human genome and mostly have uncertain origins: Long interspersed nuclear elements (LINEs, about 18,99% of the genome) encode two proteins, an RNA-binding protein (ORF1p) and a reverse transcriptase/endonuclease (ORF2p), that confer autonomous transposition activity; short interspersed nuclear elements (SINEs, about 14.66% of the genome) do not encode proteins and require proteins produced in trans by LINEs for transposition (Lander et al. 2001). Of the 3 families of LINEs, only the LINE1 family is known to be currently active (Lander et al. 2001, Beck et al. 2010). Of the SINEs, only Alu elements, which evolved from the 7SL RNA of the signal recognition particle, are known to be currently active (Lander et al. 2001, Bennett et al. 2008). Surprisingly, although retroelements can cause deleterious mutations due to insertions and recombination, their genomic elements and expression are required for embryogenesis. The envelope proteins ERVW-1 (Syncytin-1) of the HERV-W endogenous retrovirus and ERVFRD-1 (Syncytin-2) of the HERV-FRD endogenous retrovirus act to fuse cells in the trophoblast (reviewed in Gholami Barzoki et al. 2023). TEs contain binding sites for pluripotency factors (for example OCT4, SOX2, and NANOG) as well as cell lineage-specific factors (Pontis et al. 2022), In humans, a hominid-specific TE family, LTR5Hs, become transcriptionally active during specification of primordial germ cells (PGCs) and serve to bind PGC transcription factors (Xiang et al. 2022). In mice, the retroviral MERVL element is transcribed in cleavage-stage embryos and during this time MERVL regulatory DNA elements activate expression of more than one hundred genes involved in zygotic genome activation (Macfarlan et al. 2012, Sakashita et al. 2023, Yang et al. 2024). In mouse embryos, transcripts from LINE1 retroelements are required to exit the 2-cell stage by serving as scaffolds for Nucleolin (NCL) and TRIM28 (KAP1) to repress Dux expression and activate rRNA expression (Percharde et al. 2018, Chen et al. 2021). LINE1 elements are also active in expressing cell type-specific transcripts in the developing and adult human brain (Garza et al. 2023). By binding transcription activators, retroelements such as LTR5 and LTR7 can also act as cis-regulatory networks in somatic cells (reviewed in Sundaram and Wysocka 2020, Low et al. 2021, Fueyo et al. 2022). Retroelements are generally silenced transcriptionally by DNA methylation and histone modifications (reviewed in Geis and Goff 2020, Carotti et al. 2023, Stamidis and Zylicz 2023) or post-transcriptionally by RNA interference (reviewed in Geis and Goff 2020), however repressive chromatin marks are lost and retroelements are transcribed at two points during mammalian development: in early germ cells prior to meiosis and in zygotes immediately after fertilization (reviewed in Low et al. 2021). In germ cells, small RNAs of 24-31 nucleotides known as PIWI-interacting RNAs (piRNAs) are generated from transcripts of retroelements and, when bound to PIWI proteins, guide post-transcriptional decay of retroelement transcripts and re-impose chromatin modifications that repress transcription of retroelements. Endogenous retroelements are also transcriptionally silenced by zinc finger-containing proteins, KRAB-ZFPs, that bind specific DNA sequences (reviewed in Yang et al. 2017). The human genome contains 423 KRAB-ZFP genes that encode 742 KRAB-ZFP proteins that appear to evolve in response to invasion by retroelements (reviewed in Huntley et al. 2006, Lupo et al. 2013). Specific KRAB-ZFPs bind specific families of retroelements and recruit the TRIM28 scaffold protein (also known as KAP1), which assembles a complex containing the histone methylase SETDB1 and the NuRD repressor complex to silence transcription of the retroelements (reviewed in Almeida et al. 2022). The Human Silencing Hub (HUSH) complex directly binds RNA of LINE1 elements and trimethylates lysine-9 of histone H3 (H3K9) of nucleosomes assembled on the LINE1 that produced the RNA (reviewed in Seczynska and Lehner 2023). Trimethyl H3K9 (H3K9me3) is a repressive mark thus the result is de novo formation of heterochromatin at LINE1 elements. The HUSH complex also binds H3K9me3 and trimethylates H3K9 of adjacent nucleosomes, resulting in propagation of heterochromatin (reviewed in Seczynska and Lehner 2023). In mice, N6 methylation of adenosine residues in RNAs can cause destabilization of the RNA (Chelmicki et al. 2021) and transcriptional silencing of the locus that produced the RNA (Xu et al. 2021, Liu et al. 2021). The effect of N6-methyladenosine on expression of human retroelements is less clear. Xiong et al. (2021) observed that N6-methyladenosine in transcripts of young LINE1 elements increased RNA expression while N6-methyladenosine in transcripts of ancient LINE1 elements decreased RNA expression. The mechanism responsible for the difference may involve the promotion of translation of young LINE1 elements by N6-methyladenosine residues located in the 5&apos; untranslated region (Hwang et al. 2021).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep103" />
 <bp:pathwayOrder rdf:resource="#PathwayStep104" />
 <bp:pathwayOrder rdf:resource="#PathwayStep105" />
 <bp:pathwayOrder rdf:resource="#PathwayStep106" />
 <bp:pathwayOrder rdf:resource="#PathwayStep107" />
 <bp:pathwayOrder rdf:resource="#PathwayStep108" />
 <bp:pathwayOrder rdf:resource="#PathwayStep109" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction92" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction91" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction94" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction93" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction96" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction95" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction97" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence103" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regulation of endogenous retroelements by KRAB-ZFP proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Kr&#252;ppel-associated box domain (KRAB) zinc finger proteins (KRAB-ZFPs) contain a transcriptionally repressive N-terminal domain, the KRAB domain, and a C-terminal domain, the ZFP domain, that contains 2-40 zinc fingers and binds specific sequences of DNA (reviewed in Ecco et al. 2017, Yang et al. 2017). The human genome contains about 352 (Lukic et al. 2014), 378 (de Tribolet-Hardy et al. 2023), or 423 (Huntley et al. 2006) KRAB-ZFP genes, making them the largest family of transcription regulators. About two thirds or more of KRAB-ZFPs bind transposable elements (Schmitges et al. 2016, Imbeault et al. 2017, de Tribolet-Hardy et al. 2023) and KRAB-ZFPs appear to coevolve with retroelements such that a KRAB-ZFP binds and transcriptionally silences a specific set of retroelements (reviewed in Ecco et al. 2017). The number of KRAB-ZFP genes correlates with the number of retroelements in mammalian genomes and younger retroelements bind fewer KRAB-ZFPs, suggesting an &quot;arms race&quot; in which the evolution of new KRAB-ZFPs is driven by and lags the appearance of new transposable elements (Thomas and Schneider 2011, Jacobs et al. 2014, Imbeault et al. 2017, reviewed in Ecco et al. 2017, Yang et al. 2017). The repressive action of KRAB-ZFPs is mediated by the scaffold protein TRIM28 (also called KAP1), the RBCC domain of which binds the N-terminal KRAB domains of KRAB-ZFPs (Friedman et al. 1996). TRIM28 autoSUMOylates and recruits effectors, such as the histone H3 lysine-9 trimethyltransferase SETDB1 (also called ESET) (Schultz et al. 2002) and the NuRD repressor complex (Schultz et al. 2001). The HUSH complex (MPHOSPH8:TASOR:PPHLN1) plays a nonredundant role with TRIM28 in silencing some young LINE1 retroelements, which are only weakly repressed by TRIM28 or HUSH alone (Robbez-Masson et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction67">
 <bp:evidence rdf:resource="#Evidence76" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RXRA binds ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway18">
 <bp:pathwayOrder rdf:resource="#PathwayStep131" />
 <bp:pathwayOrder rdf:resource="#PathwayStep132" />
 <bp:pathwayOrder rdf:resource="#PathwayStep133" />
 <bp:pathwayOrder rdf:resource="#PathwayStep134" />
 <bp:pathwayOrder rdf:resource="#PathwayStep135" />
 <bp:pathwayOrder rdf:resource="#PathwayStep136" />
 <bp:pathwayOrder rdf:resource="#PathwayStep130" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction118" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction119" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction116" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction117" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction114" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction115" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction113" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence130" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NoRC negatively regulates rRNA expression</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Nucleolar Remodeling Complex (NoRC) comprising TIP5 (BAZ2A) and the chromatin remodeller SNF2H (SMARCA5) silences rRNA gene (reviewed in Santoro and Grummt 2001, Grummt 2007, Preuss and Pikaard 2007, Birch and Zommerdijk 2008, McStay and Grummt 2008, Grummt and Langst 2013). The TAM domain of TIP5 (BAZ2A) binds promoter-associated RNA (pRNA) transcribed from the intergenic spacer region of rDNA. The pRNA bound by TIP5 is required to direct the complex to the main promoter of the rRNA gene possibly by triple helix formation between pRNA and the rDNA. The PHD domain of TIP5 binds histone H4 acetylated at lysine-16. Transcription Termination Factor-I (TTF-I) binds to a promoter-proximal terminator (T0 site) in the rDNA and interacts with the TIP5 subunit of NoRC. NoRC also interacts with the SIN3-HDAC complex, HDAC1, HDAC2, DNMT1, and DNMT3B. DNMT3B interacts with a triple helix formed by pRNA and the rDNA. HDAC1, DNMT1, and DNMT3B have been shown to be required for proper DNA methylation of silenced rRNA gene copies, although the catalytic activity of DNMT3B was not required.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction66">
 <bp:evidence rdf:resource="#Evidence75" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CEBPA gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway19">
 <bp:pathwayOrder rdf:resource="#PathwayStep138" />
 <bp:pathwayOrder rdf:resource="#PathwayStep139" />
 <bp:pathwayOrder rdf:resource="#PathwayStep140" />
 <bp:pathwayOrder rdf:resource="#PathwayStep141" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction123" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction121" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction122" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction120" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence138" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PRC2 methylates histones and DNA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polycomb group proteins are responsible for the heritable repression of genes during development (Lee et al. 2006, Ku et al. 2008, reviewed in Simon and Kingston 2009, Margueron and Reinberg 2011, Di Croce and Helin 2013). Two major families of Polycomb complexes exist: Polycomb Repressive Complex 1 (PRC1) and Polycomb Repressive Complex 2 (PRC2). PRC1 and PRC2 each appear to comprise sets of distinct complexes that contain common core subunits and distinct accessory subunits (reviewed in Nayak et al. 2011). PRC2, through its component EZH2 or, in some complexes, EZH1 produces the initial molecular mark of repression, the trimethylation of lysine-27 of histone H3 (H3K27me3). How PRC2 is initially recruited to a locus remains unknown, however cytosine-guanine (CpG) motifs and transcripts have been suggested. Different mechanisms may be used at different loci. The trimethylated H3K27 produced by PRC2 is bound by the Polycomb subunit of PRC1. PRC1 ubiquitinates histone H2A and maintains repression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction69">
 <bp:evidence rdf:resource="#Evidence78" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MLL4-ASCOM,(MLL3-ASCOM) complex is recruited to ligand- and coactivator-bound PPARG:RXRA heterodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway16">
 <bp:pathwayOrder rdf:resource="#PathwayStep123" />
 <bp:pathwayOrder rdf:resource="#PathwayStep129" />
 <bp:pathwayComponent rdf:resource="#Pathway18" />
 <bp:pathwayComponent rdf:resource="#Pathway17" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence123" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Negative epigenetic regulation of rRNA expression</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcription of rRNA genes is controlled by epigenetic activation and repression (reviewed in McStay and Grummt 2008, Goodfellow and Zomerdijk 2012, Grummt and Langst 2013). About half of the roughly 400 rRNA genes are expressed and these have the modifications of active chromatin: unmethylated DNA and acetylated histones. Repressed genes generally have methylated DNA and histone H3 methylated at lysine-9. Regulators of repression include the eNoSC complex, SIRT1, and the NoRC complex.  SIRT1 negatively regulates rRNA expression as a subunit of the eNoSC complex, which deacetylates histone H3 and dimethylates lysine-9 of histone H3 (H3K9me2). NoRC negatively regulates rRNA expression by shifting a nucleosome near the start of rRNA transcription into a more repressive location and recruiting Histone Deacetylase 1 and 2 (HDAC1, HDAC2) and DNA Methyltransferase 1 and 3b (DNMT1, DNMT3b). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction68">
 <bp:evidence rdf:resource="#Evidence77" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LPL gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway17">
 <bp:pathwayOrder rdf:resource="#PathwayStep124" />
 <bp:pathwayOrder rdf:resource="#PathwayStep125" />
 <bp:pathwayOrder rdf:resource="#PathwayStep126" />
 <bp:pathwayOrder rdf:resource="#PathwayStep127" />
 <bp:pathwayOrder rdf:resource="#PathwayStep128" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction109" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction108" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction112" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction110" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction111" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence124" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SIRT1 negatively regulates rRNA expression</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Expression of rRNA genes is coupled to the overall metabolism of the cell by the NAD-dependent histone deacetylase SIRT1, a component of the Energy-dependent Nucleolar Silencing Complex (eNoSC) (Murayama et al. 2008, reviewed in Salminen and Kaarniranta 2009, Grummt and Voit 2010). eNoSC comprises Nucleomethylin (NML), SIRT1, and the histone methylase SUV39H1 (Murayama et al. 2008). Deacetylation and methylation of histone H3 in the chromatin of a rRNA gene by eNoSC causes reduced expression of the gene.  When glucose is low, NAD is high (NADH is low), activity of SIRT1 is high, and activity of rRNA genes is reduced. It is hypothesized that eNoSC forms on a nucleosome containing dimethylated lysine-9 on histone H3 (H3K9me2) and then eNoSC deacetylates and dimethylates the adjacent nucleosome, thus catalyzing spreading of H3K9me2 throughout the gene.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction63">
 <bp:evidence rdf:resource="#Evidence72" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLIN2 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction62">
 <bp:evidence rdf:resource="#Evidence71" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FABP4 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction65">
 <bp:evidence rdf:resource="#Evidence74" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PEX11A gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction64">
 <bp:evidence rdf:resource="#Evidence73" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GPAM gene expression is stimulated by PPARG2:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction59">
 <bp:evidence rdf:resource="#Evidence68" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ELOVL5 gene expression is stimulated by PPARG2:RXRA:MLL4(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep140">
 <bp:stepProcess rdf:resource="#BiochemicalReaction122" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep141">
 <bp:stepProcess rdf:resource="#BiochemicalReaction123" />
 <bp:stepProcess rdf:resource="#Catalysis28" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction50">
 <bp:evidence rdf:resource="#Evidence59" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PNPLA2 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction56">
 <bp:evidence rdf:resource="#Evidence65" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACSS3 gene expression is stimulated by PPARG2:RXRA:MLL4(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction55">
 <bp:evidence rdf:resource="#Evidence64" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Coactivators are recruited to liganded PPARG:RXRA heterodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction58">
 <bp:evidence rdf:resource="#Evidence67" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ANGPTL4 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction57">
 <bp:evidence rdf:resource="#Evidence66" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KMT2D,(KMT2C) complex monomethylates nucleosomes at PPARG:RXRA-bound enhancers</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction52">
 <bp:evidence rdf:resource="#Evidence61" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACSL1 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction51">
 <bp:evidence rdf:resource="#Evidence60" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MGLL gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction54">
 <bp:evidence rdf:resource="#Evidence63" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">THRSP gene expression is stimulated by PPARG2:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction53">
 <bp:evidence rdf:resource="#Evidence62" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPARG:RXRA heterodimer binds target gene loci</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#Catalysis3" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction49">
 <bp:evidence rdf:resource="#Evidence58" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CD36 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction48">
 <bp:evidence rdf:resource="#Evidence57" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AGPAT2 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction45">
 <bp:evidence rdf:resource="#Evidence54" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ABL1 phosphorylates PPARG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction44">
 <bp:evidence rdf:resource="#Evidence53" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLIN4 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction47">
 <bp:evidence rdf:resource="#Evidence56" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CIDEC gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction46">
 <bp:evidence rdf:resource="#Evidence55" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCD5 gene expression is stimulated by PPARG2:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
 <bp:stepProcess rdf:resource="#Catalysis4" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction41">
 <bp:evidence rdf:resource="#Evidence50" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SCD gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction40">
 <bp:evidence rdf:resource="#Evidence49" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADIPOQ gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction43">
 <bp:evidence rdf:resource="#Evidence52" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LPIN1 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction42">
 <bp:evidence rdf:resource="#Evidence51" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DGAT2 gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction38">
 <bp:evidence rdf:resource="#Evidence47" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LIPE gene expression is stimulated by PPARG:RXRA:MLL4,(MLL3)-ASCOM complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction37">
 <bp:evidence rdf:resource="#Evidence43" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the MLL4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction39">
 <bp:evidence rdf:resource="#Evidence48" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PHLDA1 binds PPARG</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis28">
 <bp:controlled rdf:resource="#BiochemicalReaction123" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis27">
 <bp:controlled rdf:resource="#BiochemicalReaction121" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis26">
 <bp:controlled rdf:resource="#BiochemicalReaction119" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis25">
 <bp:controlled rdf:resource="#BiochemicalReaction115" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis24">
 <bp:controlled rdf:resource="#BiochemicalReaction114" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis23">
 <bp:controlled rdf:resource="#BiochemicalReaction112" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis22">
 <bp:controlled rdf:resource="#BiochemicalReaction110" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis21">
 <bp:controlled rdf:resource="#BiochemicalReaction109" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis20">
 <bp:controlled rdf:resource="#BiochemicalReaction107" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction34">
 <bp:evidence rdf:resource="#Evidence40" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the SET1B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction33">
 <bp:evidence rdf:resource="#Evidence39" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PAXIP1:PAGR1 complex, NCOA6 and KDM6A bind MLL4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction36">
 <bp:evidence rdf:resource="#Evidence42" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BOD1L1 binds SET1A complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction35">
 <bp:evidence rdf:resource="#Evidence41" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCFC1 binds SET1A complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction30">
 <bp:evidence rdf:resource="#Evidence36" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CXXC1 and WDR82 bind SET1B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction32">
 <bp:evidence rdf:resource="#Evidence38" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CXXC1 and WDR82 bind SET1A complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction31">
 <bp:evidence rdf:resource="#Evidence37" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the SET1A complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction27">
 <bp:evidence rdf:resource="#Evidence33" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKAP8L binds MLL1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction26">
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MEN1 binds MLL1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction29">
 <bp:evidence rdf:resource="#Evidence35" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PAXIP1:PAGR1 complex, NCOA6 and KDM6A bind MLL3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction28">
 <bp:evidence rdf:resource="#Evidence34" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MEN1 binds MLL2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis19">
 <bp:controlled rdf:resource="#BiochemicalReaction104" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis18">
 <bp:controlled rdf:resource="#BiochemicalReaction102" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis17">
 <bp:controlled rdf:resource="#BiochemicalReaction98" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis16">
 <bp:controlled rdf:resource="#BiochemicalReaction96" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis15">
 <bp:controlled rdf:resource="#BiochemicalReaction93" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis14">
 <bp:controlled rdf:resource="#BiochemicalReaction90" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis13">
 <bp:controlled rdf:resource="#BiochemicalReaction89" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis12">
 <bp:controlled rdf:resource="#BiochemicalReaction88" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis11">
 <bp:controlled rdf:resource="#BiochemicalReaction87" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis10">
 <bp:controlled rdf:resource="#BiochemicalReaction86" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction23">
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCFC1, HCFC2 bind the MLL1:MEN1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction22">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKAP8L binds MLL2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction25">
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the GCN5-ATAC complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction24">
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the PCAF-ATAC complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction21">
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BOD1 binds SET1B complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction20">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PSIP1 binds MLL1 and MEN1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the WRAD complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TASP1 cleaves KMT2A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the NSL complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the RBBP5:ASH2L heterodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PSIP1 binds MEN1 associated with MLL2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction109">
 <bp:evidence rdf:resource="#Evidence126" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">eNoSC deacetylates histone H3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep100">
 <bp:stepProcess rdf:resource="#BiochemicalReaction90" />
 <bp:stepProcess rdf:resource="#Catalysis14" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction107">
 <bp:evidence rdf:resource="#Evidence122" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DNMT3A:DNMT3L in nascent RNA transcript:MeR-PIWIL4:2&apos;-O-methyl-piRNA:SPOCD1:DNMT3A:DNMT3L methylates cytosine in DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep101">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction108">
 <bp:evidence rdf:resource="#Evidence125" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of energy-dependent Nucleolar Silencing Complex (eNoSC)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep102">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction105">
 <bp:evidence rdf:resource="#Evidence119" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HUSH complex binds LINE1 (L1) RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep103">
 <bp:stepProcess rdf:resource="#BiochemicalReaction91" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction106">
 <bp:evidence rdf:resource="#Evidence121" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PIWIL4:piRNA binds nascent LINE1 pre-RNA and recruits SPOCD1, C19ORF84, DNMT3A, DNMT3L, the NURD complex, and the BAF complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep104">
 <bp:stepProcess rdf:resource="#BiochemicalReaction92" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction103">
 <bp:evidence rdf:resource="#Evidence117" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">me3-K16-ATF7IP:SETDB1 and MORC2 bind MPHOSPH8 (MPP8) in HUSH complex:L1HS,L1PA2,3 heterochromatin</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep105">
 <bp:stepProcess rdf:resource="#BiochemicalReaction93" />
 <bp:stepProcess rdf:resource="#Catalysis15" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction104">
 <bp:evidence rdf:resource="#Evidence118" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SETDB1 in me3-K16-ATF7IP:SETDB1:MORC2:HUSH complex:L1 RNA trimethylates lysine-9 of histone H3 (H3K9me3)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cleaved KMT2B dimers translocate to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep106">
 <bp:stepProcess rdf:resource="#BiochemicalReaction94" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction101">
 <bp:evidence rdf:resource="#Evidence115" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPHOSPH8 (MPP8) in HUSH complex binds histone H3 trimethyl-lysine 9 (H3K9me3) in L1HS,L1PA2,3 heterochromatin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PAXIP1 binds PAGR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep107">
 <bp:stepProcess rdf:resource="#BiochemicalReaction95" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction102">
 <bp:evidence rdf:resource="#Evidence116" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EHMT1,EHMT2 trimethylates lysine-16 of ATF7IP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the MLL3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep108">
 <bp:stepProcess rdf:resource="#BiochemicalReaction96" />
 <bp:stepProcess rdf:resource="#Catalysis16" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the MLL2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep109">
 <bp:stepProcess rdf:resource="#BiochemicalReaction97" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction100">
 <bp:evidence rdf:resource="#Evidence114" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPHOSPH8 of the HUSH complex bound to retroelement chromatin binds ZCCHC8 of the NEXT complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cleaved KMT2A dimers translocate to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep110">
 <bp:stepProcess rdf:resource="#Pathway14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep111">
 <bp:stepProcess rdf:resource="#Catalysis17" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction98" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep112">
 <bp:stepProcess rdf:resource="#BiochemicalReaction99" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep113">
 <bp:stepProcess rdf:resource="#BiochemicalReaction100" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep114">
 <bp:stepProcess rdf:resource="#BiochemicalReaction101" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep115">
 <bp:stepProcess rdf:resource="#BiochemicalReaction102" />
 <bp:stepProcess rdf:resource="#Catalysis18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep116">
 <bp:stepProcess rdf:resource="#BiochemicalReaction103" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep117">
 <bp:stepProcess rdf:resource="#BiochemicalReaction104" />
 <bp:stepProcess rdf:resource="#Catalysis19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep118">
 <bp:stepProcess rdf:resource="#BiochemicalReaction105" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep119">
 <bp:stepProcess rdf:resource="#Pathway15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep120">
 <bp:stepProcess rdf:resource="#BiochemicalReaction106" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep121">
 <bp:stepProcess rdf:resource="#BiochemicalReaction107" />
 <bp:stepProcess rdf:resource="#Catalysis20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep122">
 <bp:stepProcess rdf:resource="#Pathway16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep123">
 <bp:stepProcess rdf:resource="#Pathway17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep124">
 <bp:stepProcess rdf:resource="#BiochemicalReaction108" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep125">
 <bp:stepProcess rdf:resource="#BiochemicalReaction109" />
 <bp:stepProcess rdf:resource="#Catalysis21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep126">
 <bp:stepProcess rdf:resource="#Catalysis22" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction110" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep127">
 <bp:stepProcess rdf:resource="#BiochemicalReaction111" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep128">
 <bp:stepProcess rdf:resource="#Catalysis23" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction112" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction123">
 <bp:evidence rdf:resource="#Evidence142" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PRC2 trimethylates histone H3 at lysine-27</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep129">
 <bp:stepProcess rdf:resource="#Pathway18" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction121">
 <bp:evidence rdf:resource="#Evidence140" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DNMT1,3A,3B:PRC2 methylates cytosine and histone H3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction122">
 <bp:evidence rdf:resource="#Evidence141" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PRC2 recruits DNA methyltransferases</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction120">
 <bp:evidence rdf:resource="#Evidence139" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polycomb Repressive Complex 2 (PRC2) Is recruited to chromatin</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep130">
 <bp:stepProcess rdf:resource="#BiochemicalReaction113" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep131">
 <bp:stepProcess rdf:resource="#BiochemicalReaction114" />
 <bp:stepProcess rdf:resource="#Catalysis24" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep132">
 <bp:stepProcess rdf:resource="#BiochemicalReaction115" />
 <bp:stepProcess rdf:resource="#Catalysis25" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep133">
 <bp:stepProcess rdf:resource="#BiochemicalReaction116" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction118">
 <bp:evidence rdf:resource="#Evidence136" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cleavage of intergenic spacer RNA to yield fragments of 150-300 nucleotides</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep134">
 <bp:stepProcess rdf:resource="#BiochemicalReaction117" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction119">
 <bp:evidence rdf:resource="#Evidence137" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcription of intergenic spacer of the rRNA gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction116">
 <bp:evidence rdf:resource="#Evidence134" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TTF-I binds to the Sal Box</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep135">
 <bp:stepProcess rdf:resource="#BiochemicalReaction118" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction117">
 <bp:evidence rdf:resource="#Evidence135" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleolar Remodelling Complex (NoRC) binds intergenic region of rDNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep136">
 <bp:stepProcess rdf:resource="#BiochemicalReaction119" />
 <bp:stepProcess rdf:resource="#Catalysis26" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction114">
 <bp:evidence rdf:resource="#Evidence132" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NoRC:HDAC:DNMT deacetylates histone H4 and methylates histone H3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep137">
 <bp:stepProcess rdf:resource="#Pathway19" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction115">
 <bp:evidence rdf:resource="#Evidence133" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NoRC:HDAC:DNMT methylates cytosine of the rRNA genes</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep138">
 <bp:stepProcess rdf:resource="#BiochemicalReaction120" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction112">
 <bp:evidence rdf:resource="#Evidence129" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">eNoSC dimethylates histone H3 at lysine-9</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep139">
 <bp:stepProcess rdf:resource="#BiochemicalReaction121" />
 <bp:stepProcess rdf:resource="#Catalysis27" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction113">
 <bp:evidence rdf:resource="#Evidence131" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MBD2 binds methylcytosine in chromatin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction110">
 <bp:evidence rdf:resource="#Evidence127" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SIRT1 deacetylates TAF1B in SL1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction111">
 <bp:evidence rdf:resource="#Evidence128" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RRP8 binds RNA</bp:displayName>
</bp:BiochemicalReaction>
</rdf:RDF>